MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326943 | Name: Azimilide HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Azimilide, also known as NE 10064, a potassium channel blocker potentially for the treatment of arrhythmia. Azimilide has been studied for its anti-arrhythmic effects: its converts and maintains sinus rhythm in patients with atrial arrhythmias; and it reduces the frequency and severity of ventricular arrhythmias in patients with implanted cardioverter-defibrillators. Azimilide's most important adverse effect is torsades de pointes, which is a form of ventricular tachycardia.

Chemical Structure

Azimilide HCl
Azimilide HCl
CAS#149888-94-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 326943

Name: Azimilide HCl

CAS#: 149888-94-8 (HCl)

Chemical Formula: C23H30Cl3N5O3

Exact Mass: 0.0000

Molecular Weight: 530.88

Elemental Analysis: C, 52.04; H, 5.70; Cl, 20.03; N, 13.19; O, 9.04

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Azimilide Hydrochloride; NE 10064; NE-10064; NE10064.
IUPAC/Chemical Name
2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, dihydrochloride
InChi Key
HHPSICLSNHCSNZ-BYEGLACWSA-N
InChi Code
InChI=1S/C23H28ClN5O3.2ClH/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18;;/h4-9,16H,2-3,10-15,17H2,1H3;2*1H/b25-16+;;
SMILES Code
O=C1N(CCCCN2CCN(C)CC2)C(CN1/N=C/C3=CC=C(C4=CC=C(Cl)C=C4)O3)=O.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 149908-53-2 (Azimilide) 149888-94-8 (Azimilide Hydrochloride)

Preparing Stock Solutions

The following data is based on the product molecular weight 530.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Li M, Tang YQ, Du RH, Shi FH, Hussein HK, Dai DZ, Dai Y. CPUY11018, an azimilide derivative, ameliorates isoproterenol-induced cardiac insufficiency through relieving dysfunctional mitochondria and endoplasmic reticulum. J Pharm Pharmacol. 2015 Aug;67(8):1029-41. doi: 10.1111/jphp.12401. Epub 2015 Apr 1. PubMed PMID: 25828246. 2: Watanabe Y, Kimura J. Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes. J Pharmacol Sci. 2010;114(1):111-4. Epub 2010 Aug 11. PubMed PMID: 20710119. 3: Cannom DS, Gidney B. Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works. J Am Coll Cardiol. 2008 Sep 23;52(13):1084-5. doi: 10.1016/j.jacc.2008.07.003. PubMed PMID: 18848142. 4: Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P; Shock Inhibition Evaluation with Azimilide Investigators. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008 Sep 23;52(13):1076-83. doi: 10.1016/j.jacc.2008.05.055. PubMed PMID: 18848141. 5: Chevalier P, Dubieff AD, Piqueras E, Pineau J, Rivard L, Morel E, Bui-Xan B, Timour Q. The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy. J Cardiovasc Pharmacol. 2007 Dec;50(6):629-32. PubMed PMID: 18091578. 6: Nishida A, Reien Y, Ogura T, Uemura H, Tamagawa M, Yabana H, Nakaya H. Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts. J Pharmacol Sci. 2007 Nov;105(3):229-39. Epub 2007 Oct 27. PubMed PMID: 17965539. 7: Page RL, Pritchett EL, Connolly S, Wilkinson WE; SVA-4 Investigators. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. J Cardiovasc Electrophysiol. 2008 Feb;19(2):172-7. Epub 2007 Oct 3. PubMed PMID: 17916138. 8: Kaźmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2007 Aug;30(8):1043-6. PubMed PMID: 17669094. 9: Lombardi F, Borggrefe M, Ruzyllo W, Lüderitz B; A-COMET-II Investigators. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006 Sep;27(18):2224-31. Epub 2006 Aug 25. PubMed PMID: 16935870. 10: Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR, Borggrefe M, Dorian P, Camm AJ; Azimilide Trials Investigators. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol. 2006 Aug 1;48(3):471-7. Epub 2006 Jul 12. PubMed PMID: 16875971. 11: Kerr CR, Connolly SJ, Kowey P, Page RL, Pritchett EL, Ruda MY, Ruzyllo W, Wilkinson WE; A-STAR Investigators. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006 Jul 15;98(2):215-8. Epub 2006 May 19. PubMed PMID: 16828595. 12: Löfberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006 Jul;8(7):549-57. PubMed PMID: 16798770. 13: Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE; A-COMET-I Investigators. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J. 2006 May;151(5):1043-9. PubMed PMID: 16644334. 14: Ducroq J, Rouet R, Puddu PE, Sallé L, Tabourel C, Ducouret P, Gérard JL. Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. Eur J Pharmacol. 2005 Aug 22;518(2-3):165-74. PubMed PMID: 16083874. 15: Riley P, Figary PC, Entwisle JR, Roe AL, Thompson GA, Ohashi R, Ohashi N, Moorehead TJ. The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95. PubMed PMID: 16052551. 16: Light P. Azimilide (Procter & Gamble). IDrugs. 2000 Dec;3(12):1534-44. PubMed PMID: 16037862. 17: Toothaker RD, Corey AE, Valentine SN, Agnew JR, Parekh N, Moehrke W, Thompson GA, Powell JH. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. J Clin Pharmacol. 2005 Jul;45(7):773-80. PubMed PMID: 15951467. 18: Carlson M. Azimilide dihydrochloride. Expert Rev Cardiovasc Ther. 2005 May;3(3):387-91. PubMed PMID: 15889966. 19: VerNooy RA, Mangrum JM. Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Feb;5(1):75-84. Review. PubMed PMID: 15720225. 20: Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH; SHIELD Investigators. Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. Am J Cardiol. 2005 Jan 15;95(2):274-6. PubMed PMID: 15642569.